Answers are grounded in this paper and cite their sources.
Fourty-four patients with acute myeloblastic leukaemia were treated with RP 22050, a new, semisynthetic derivative of daunorubicin. Complete remissions were achieved in 20 patients (45%). The median dose given was 23 mg/kg. The toxicity of RP 22050 is mainly haematological. Resistance rather than death in aplasia seemed to be the cause of failure of therapy.
No takes yet. Share an insight, caveat, or question.
Jacquillat et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: